Publications by authors named "Christopher D O'Brien"

Claim this Profile
E
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
Silvio Danese, Bruce E Sands, Maria T Abreu, Christopher D O'Brien, Ivana Bravatà

Clin Gastroenterol Hepatol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
William J Sandborn, Brian G Feagan, Silvio Danese, Christopher D O'Brien, Elyssa Ott

Inflamm Bowel Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
Remo Panaccione, Silvio Danese, William J Sandborn, Christopher D O'Brien, Yiying Zhou

Aliment Pharmacol Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results.
Jeffrey S Hyams, Christopher D O'Brien, Lakshmi Padgett, Joel R Rosh, Dan Turner

Crohns Colitis 360· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Bruce E Sands, William J Sandborn, Remo Panaccione, Christopher D O'Brien, Hongyan Zhang

N Engl J Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Bruce E Sands, William J Sandborn, Brian G Feagan, Gary R Lichtenstein, Hongyan Zhang, Christopher D O'Brien

J Crohns Colitis· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.
Andreas Eich, Veronika Urban, Marek Jutel, Jiri Vlcek, Jae Jeong Shim, Christopher D O'Brien

COPD· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: a randomized controlled trial.
Randall W Brown, Christopher D O'Brien, Ubaldo J Martin, Tom Uryniak, Kathy L Lampl

J Allergy Clin Immunol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Piotr Kuna, Martin Jenkins, Christopher D O'Brien, William A Fahy

Respir Med· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
Claus Vogelmeier, Teresita O Aquino, Christopher D O'Brien, John Perrett, Kulasiri A Gunawardena

COPD· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budesonide/formoterol pressurized metered-dose inhaler versus budesonide: a randomized controlled trial in black patients with asthma.
Sheldon L Spector, Ubaldo J Martin, Tom Uryniak, Christopher D O'Brien

J Asthma· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial.
James Zangrilli, Lyndon E Mansfield, Tom Uryniak, Christopher D O'Brien

Ann Allergy Asthma Immunol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once- vs twice-daily budesonide/formoterol in 6- to 15-year-old patients with stable asthma.
Nemr S Eid, Michael J Noonan, Bradley Chipps, Bhash Parasuraman, Christopher J Miller, Christopher D O'Brien

Pediatrics· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children.
William E Berger, Jeffrey G Leflein, David E Geller, Bhash Parasuraman, Christopher J Miller, Christopher D O'Brien

Allergy Asthma Proc· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The functionality of a budesonide/formoterol pressurized metered-dose inhaler with an integrated actuation counter.
Shailen Shah, Martha White, Tom Uryniak, Christopher D O'Brien

Allergy Asthma Proc· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can patients with asthma feel inhaler therapy working right away? Two clinical trials testing the effect of timing of assessment on patient perception.
Nancy Kline Leidy, Benjamin Gutierrez, Kathy Lampl, Tom Uryniak, Christopher D O'Brien

J Asthma· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting clinical trial results of patient-perceived onset of effect in asthma: methods and results of a Delphi panel.
Gale Harding, Nancy Kline Leidy, David Meddis, Leah Kleinman, Samuel Wagner, Christopher D O'Brien

Curr Med Res Opin· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients.
Stephen P Peters, Bruce M Prenner, William S Mezzanotte, Paula Martin, Christopher D O'Brien

Allergy Asthma Proc· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Availability of the combination of formoterol and budesonide in the United States of America.
Chris M Blango, Christopher D O'Brien

Allergy Asthma Proc· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.
Jonathan Corren, Phillip E Korenblat, Christopher J Miller, Christopher D O'Brien, William S Mezzanotte

Clin Ther· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
Michael Noonan, Lanny J Rosenwasser, Paula Martin, Christopher D O'Brien, Liza O'Dowd

Drugs· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrapatient symptom variability in adults and children with asthma: results of a survey.
Philip Marcus, Kevin R Murphy, Abid Rahman, Christopher D O'Brien

Adv Ther· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of immunoreceptor tyrosine-based inhibitory motifs of PECAM-1 in PECAM-1-dependent cell migration.
Christopher D O'Brien, Gaoyuan Cao, Antonis Makrigiannakis, Horace M DeLisser

Am J Physiol Cell Physiol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PECAM-1-dependent neutrophil transmigration is independent of monolayer PECAM-1 signaling or localization.
Christopher D O'Brien, Poay Lim, Jing Sun, Steven M Albelda

Blood· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration.
Gaoyuan Cao, Christopher D O'Brien, Zhao Zhou, Samuel M Sanders, Jordan N Greenbaum

Am J Physiol Cell Physiol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis